By: Stephanie Chiu and Elissa Tam, PharmD Candidates c/o 2015 — According to the Dartmouth Atlas project, health care spending in the United States has risen dramatically and yet health outcomes are not improving; meanwhile, many other countries that spend far less per person than the United States have better health outcomes.1 Studies have since…

Submit an article and letter of intent To [email protected] View the application: http://rhochistj.org/RhoChiPost/application/ Below are some FAQ; please email us for any other concerns! Who can join the Rho Chi post? Do I have to be a member of Rho Chi? You do not have to be a member of the Rho Chi Honor Society…

By: Melissa Roy Co-Copy Editor [Graphics focused] — Many people do not realize the opportunities that are available to pharmacists. Joanne Bollhofer-White has taken the path less traveled by entering into the Air Force. Her position in the military has allowed her to travel all over the country while serving her country. The Air Force…

By: Jacqueline Meaney, PharmD Candidate c/o 2015, University at Buffalo: School of Pharmacy and Pharmaceutical Sciences — Psychotropic medications are typically used in conjunction with cognitive behavioral therapy to treat behavioral problems that affect children with autism spectrum disorder (ASD). Symptoms of ASD typically include a need for routines (change intolerance), difficulty with verbal and…

By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk…

Got something interesting to say? Want to publish your poster presentation? Want to review a new drug on the market? Then write to us at [email protected] Visit our website: http://rhochistj.org/RhoChiPost/Topics/  

By: Andrew Leong, Staff Writer — This year, the FDA approved three new antibiotics to treat acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus, including MRSA. They are dalbavancin (DalvanceTM), tedizolid phosphate (SivextroTM), and oritavancin (OrbactivTM). Dalbavancin was approved on May 23, 2014 and is administered intravenously in two doses (1000…